APA (7th ed.) Citation

Bradshaw, D., Abramowicz, I., Bremner, S., Verma, S., Gilleece, Y., Kirk, S., . . . Perry, N. (2023). Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. PLoS ONE, 18(7), 1. https://doi.org/10.1371/journal.pone.0288598

Chicago Style (17th ed.) Citation

Bradshaw, Daniel, et al. "Hepmarc: A 96 Week Randomised Controlled Feasibility Trial of Add-on Maraviroc in People with HIV and Non-alcoholic Fatty Liver Disease." PLoS ONE 18, no. 7 (2023): 1. https://doi.org/10.1371/journal.pone.0288598.

MLA (9th ed.) Citation

Bradshaw, Daniel, et al. "Hepmarc: A 96 Week Randomised Controlled Feasibility Trial of Add-on Maraviroc in People with HIV and Non-alcoholic Fatty Liver Disease." PLoS ONE, vol. 18, no. 7, 2023, p. 1, https://doi.org/10.1371/journal.pone.0288598.